In this comprehensive presentation, James K. Mangan, MD, provides a detailed examination of the myelodysplastic syndromes (MDS) as recorded at Ash 2017, beginning with novel diagnostics and molecular prognostic information,including an overview of the IPSS-R, a risk stratification tool, and extending to the goals and algorithms for the treatment of primary, intermediate and high-risk MDS, as well as refractory disease. Dr. Mangan closes with a discussion of novel approaches to MDS and accruing trials for the syndromes at the Abramson Cancer Center.
Related Links:
Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Connect on Doximity
Published
March 8, 2018
Created by
BROADCASTMED